449 related articles for article (PubMed ID: 29559971)
1. Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.
Wolf BJ; Choi JE; Exley MA
Front Immunol; 2018; 9():384. PubMed ID: 29559971
[TBL] [Abstract][Full Text] [Related]
2. CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.
Hara A; Koyama-Nasu R; Takami M; Toyoda T; Aoki T; Ihara F; Kobayashi M; Hirono S; Matsutani T; Nakayama T; Iwadate Y; Motohashi S
Cancer Immunol Immunother; 2021 May; 70(5):1239-1254. PubMed ID: 33128583
[TBL] [Abstract][Full Text] [Related]
3. Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.
Zhu Y; Smith DJ; Zhou Y; Li YR; Yu J; Lee D; Wang YC; Di Biase S; Wang X; Hardoy C; Ku J; Tsao T; Lin LJ; Pham AT; Moon H; McLaughlin J; Cheng D; Hollis RP; Campo-Fernandez B; Urbinati F; Wei L; Pang L; Rezek V; Berent-Maoz B; Macabali MH; Gjertson D; Wang X; Galic Z; Kitchen SG; An DS; Hu-Lieskovan S; Kaplan-Lefko PJ; De Oliveira SN; Seet CS; Larson SM; Forman SJ; Heath JR; Zack JA; Crooks GM; Radu CG; Ribas A; Kohn DB; Witte ON; Yang L
Cell Stem Cell; 2019 Oct; 25(4):542-557.e9. PubMed ID: 31495780
[TBL] [Abstract][Full Text] [Related]
4. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.
Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S
Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315
[TBL] [Abstract][Full Text] [Related]
5. Type II Natural Killer T Cells Contribute to Protection Against Systemic Methicillin-Resistant
Genardi S; Visvabharathy L; Cao L; Morgun E; Cui Y; Qi C; Chen YH; Gapin L; Berdyshev E; Wang CR
Front Immunol; 2020; 11():610010. PubMed ID: 33312179
[TBL] [Abstract][Full Text] [Related]
6. Immune Networks and Therapeutic Targeting of iNKT Cells in Cancer.
Fujii SI; Shimizu K
Trends Immunol; 2019 Nov; 40(11):984-997. PubMed ID: 31676264
[TBL] [Abstract][Full Text] [Related]
7. TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells.
Delfanti G; Cortesi F; Perini A; Antonini G; Azzimonti L; de Lalla C; Garavaglia C; Squadrito ML; Fedeli M; Consonni M; Sesana S; Re F; Shen H; Dellabona P; Casorati G
Sci Immunol; 2022 Aug; 7(74):eabn6563. PubMed ID: 35984893
[TBL] [Abstract][Full Text] [Related]
8. Roles of NKT cells in cancer immunotherapy.
Bae EA; Seo H; Kim IK; Jeon I; Kang CY
Arch Pharm Res; 2019 Jul; 42(7):543-548. PubMed ID: 30859410
[TBL] [Abstract][Full Text] [Related]
9. Using agonists for iNKT cells in cancer therapy.
Painter GF; Burn OK; Hermans IF
Mol Immunol; 2021 Feb; 130():1-6. PubMed ID: 33340930
[TBL] [Abstract][Full Text] [Related]
10. Exploiting CD1-restricted T cells for clinical benefit.
Exley MA; Dellabona P; Casorati G
Mol Immunol; 2021 Apr; 132():126-131. PubMed ID: 33582549
[TBL] [Abstract][Full Text] [Related]
11. The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.
Pyz E; Naidenko O; Miyake S; Yamamura T; Berberich I; Cardell S; Kronenberg M; Herrmann T
J Immunol; 2006 Jun; 176(12):7447-55. PubMed ID: 16751390
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.
Webb TJ; Bieler JG; Schneck JP; Oelke M
J Immunol Methods; 2009 Jul; 346(1-2):38-44. PubMed ID: 19446558
[TBL] [Abstract][Full Text] [Related]
13. Anti-Vα24Jα18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an FcγRII (CD32)-dependent Manner.
Takami M; Aoki T; Nishimura K; Tanaka H; Onodera A; Motohashi S
Cancer Res Commun; 2024 Feb; 4(2):446-459. PubMed ID: 38319156
[TBL] [Abstract][Full Text] [Related]
14. Invariant and noninvariant natural killer T cells exert opposite regulatory functions on the immune response during murine schistosomiasis.
Mallevaey T; Fontaine J; Breuilh L; Paget C; Castro-Keller A; Vendeville C; Capron M; Leite-de-Moraes M; Trottein F; Faveeuw C
Infect Immun; 2007 May; 75(5):2171-80. PubMed ID: 17353286
[TBL] [Abstract][Full Text] [Related]
15. Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.
Stolk D; van der Vliet HJ; de Gruijl TD; van Kooyk Y; Exley MA
Front Immunol; 2018; 9():1990. PubMed ID: 30298063
[TBL] [Abstract][Full Text] [Related]
16. Antigen Presentation by CD1 Lipids, T Cells, and NKT Cells in Microbial Immunity.
Cohen NR; Garg S; Brenner MB
Adv Immunol; 2009; 102():1-94. PubMed ID: 19477319
[TBL] [Abstract][Full Text] [Related]
17. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control.
Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y
Front Immunol; 2018; 9():1266. PubMed ID: 29928278
[TBL] [Abstract][Full Text] [Related]
18. The regulatory role of invariant NKT cells in tumor immunity.
McEwen-Smith RM; Salio M; Cerundolo V
Cancer Immunol Res; 2015 May; 3(5):425-35. PubMed ID: 25941354
[TBL] [Abstract][Full Text] [Related]
19. Strategy of lipid recognition by invariant natural killer T cells: 'one for all and all for one'.
Mallevaey T; Selvanantham T
Immunology; 2012 Jul; 136(3):273-82. PubMed ID: 22671023
[TBL] [Abstract][Full Text] [Related]
20. The Role of Invariant NKT in Autoimmune Liver Disease: Can Vitamin D Act as an Immunomodulator?
Smyk DS; Mavropoulos A; Mieli-Vergani G; Vergani D; Lenzi M; Bogdanos DP
Can J Gastroenterol Hepatol; 2018; 2018():8197937. PubMed ID: 30046564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
